Informed Consent I — The Benefits, Honestly Plausible Clinician sign-off

Real informed consent isn't the best story someone can tell you about these treatments — it's the accurate one. This lesson lays out what has actually been measured, how large the effects were, and how sure the science really is. You deserve to walk in hopeful and clear-eyed at the same time.

What "benefit" actually means here

When researchers say a treatment "worked," they usually mean a group of people improved on average on a standardized scale — PTSD severity, depression scores, overall functioning. Averages are real, but they hide the spread: some people improve dramatically, some moderately, some barely, and a few not at all. A number like a large effect size tells you the typical result in a study — never a promise about your result. Keep that lens on every figure below.

MDMA-assisted therapy for PTSD: the strongest signal we have Plausible

The best-designed trial to date — a randomized, double-blind, placebo-controlled phase 3 study — paired MDMA with structured therapy (three preparatory and nine integrative sessions) and found a large reduction in PTSD severity versus placebo-with-therapy (Cohen's d ≈ 0.91). In that trial, investigators did not detect abuse, suicidality, or heart-rhythm (QT) signals^[1]. Read that last part carefully: "no QT signal in one trial" is not a clean bill of cardiac health. MDMA reliably raises heart rate and blood pressure during a session, and — because it floods the serotonin system — it can be dangerous when combined with SSRIs, MAOIs, or other serotonergic medications (serotonin syndrome). Those are exactly the risks that make medical screening and active monitoring non-negotiable, not optional. A systematic review of phase II/III trials found consistently greater PTSD improvement with MDMA-assisted therapy, and 41.7% to 83.3% of participants no longer met criteria for a PTSD diagnosis afterward^[2]. For a veteran carrying combat trauma, a loss of diagnosis is a genuinely meaningful outcome — but remember it is a group result, not a promise for any one person.

Here is the honesty that has to ride alongside that hope. A 2026 meta-analysis pooling these trials confirmed reduced PTSD severity (SMD −1.19) but rated the overall certainty of the evidence as VERY LOW, calling for larger, active-controlled trials before we treat this as settled^[3]. Promising is not the same as proven.

Psilocybin for depression: a real signal, not a cure Plausible

A small randomized trial (24 evaluable participants) of psilocybin-assisted therapy for major depression found large antidepressant effects four weeks after treatment^[4]. A larger phase 2b trial (233 people) found a single 25 mg dose reduced depression scores more than a 1 mg comparison dose at three weeks^[5]. That is a genuine signal for treatment-resistant depression.

But the same larger trial is exactly why we don't oversell it: adverse events occurred in 77% of participants, and suicidal ideation or behavior showed up across all dose groups^[5]. A benefit and a serious risk can live in the same study. Psilocybin is Schedule I federally — the outcomes above happened under clinical supervision, and that supervision is part of why they looked the way they did.

Ketamine and esketamine: the one with an approved cousin Plausible

An international expert synthesis found that ketamine and esketamine have genuine rapid-onset efficacy in treatment-resistant depression — but with real safety and tolerability concerns that require an appropriate setting and active monitoring^[6]. This is the corner of this field with the firmest regulatory footing: ketamine is a Schedule III medication, and esketamine (brand name Spravato) is FDA-approved for treatment-resistant depression under a restricted, monitored program. That approval covers esketamine specifically — it does not make psilocybin, MDMA, LSD, DMT, or ibogaine approved or legal.

How sure is "sure"? Reading the evidence grades

Throughout this course you'll see a pill next to each claim. Established means repeatedly confirmed in strong trials. Plausible means real, encouraging evidence that isn't settled yet — where most of these psychedelic findings sit today. Hypothesis means it's an idea being tested, not a finding you can lean on. Notice that even the MDMA and psilocybin results — the strongest in the field — are Plausible, not Established, because the trials are small, some were open-label (everyone knew what they got, which tends to inflate optimism), and the pooled certainty was rated very low^[3].

What has NOT been shown — so no one oversells you

Two claims you may hear elsewhere do not have the evidence to back them, and honesty means saying so plainly:

"Detox or terrain prep improves your outcome." Hypothesis This is untested. There is no trial showing that cleansing, chelation, or supplement protocols make a psychedelic session work better or last longer. Treat it as an unproven idea, not a step that earns you a better result.

"These drugs regrow your brain (neuroplasticity/BDNF)." Hypothesis The rodent and lab data are interesting, but a 2024 meta-analysis in humans found no peripheral (blood-measured) change in BDNF after psychedelics. In people, the "rewires your brain" story is not established — hold it as a hypothesis, not a benefit you're being given.

Carry this out of the lesson: Believe the signal, respect the uncertainty — hope and honesty are allowed to sit in the same chair.